Contraception
Volume 80, Issue 1 , Pages 18-24 , July 2009

Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen

  • László Hernádi

      Affiliations

    • Department of Obstetrics and Gynaecology, Markhot F. Heves County Hospital, Széchenyi út 27, 3300 Eger, Hungary
    • ,
  • Joachim Marr

      Affiliations

    • Clinical Development Women's Healthcare, Bayer Schering Pharma AG, D-13342 Berlin, Germany
    • Corresponding Author InformationCorresponding author. Medical Development Female Contraception, Bayer Schering Pharma AG, D-13342 Berlin, Germany. Tel.: +49 30 468 17617; fax: +49 30 468 15348.
    • ,
  • Dietmar Trummer

      Affiliations

    • Global Clinical Statistics, Bayer Schering Pharma AG, D-13342 Berlin, Germany
    • ,
  • Vincenzo De Leo

      Affiliations

    • Department of Pediatrics Obstetrics and Reproductive Medicine, Division of Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy
    • ,
  • Felice Petraglia

      Affiliations

    • Department of Pediatrics Obstetrics and Reproductive Medicine, Division of Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy

Received 27 May 2008 ,Revised 23 January 2009 ,Accepted 28 January 2009.

References 

  1. Shvarts S, Besinque K, Atkinson R, Gill MA. New advances in contraception. Insights. 2002;11–22
  2. Trussell J. Contraceptive efficacy. In:  Hatcher RA,  Trussell J,  Nelson AL,  Cates W,  Stewart FH,  Kowal D editor. Contraceptive Technology: Nineteenth Revised Edition. New York (NY): Ardent Media; 2007;p. 747–826
  3. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29–38
  4. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception. 1995;51:99–110
  5. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54:243–251
  6. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354
  7. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124–134
  8. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25–34
  9. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105–111
  10. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med. 2003;48:79–85
  11. Fruzzetti F, Lello S, Lazzarini V, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception. 2007;75:199–203
  12. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51
  13. Borges LE, Andrade RP, Aldrighi JM, et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception. 2006;74:446–450
  14. Boschitsch E, Skarabis H, Wuttke W, Heithecker R. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care. 2000;5(Suppl 3):34–40
  15. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191–198
  16. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71:409–416
  17. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–421
  18. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501
  19. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3 mg/20 μg (24/4 day regimen). Drugs. 2007;67:1749–1765
  20. The Mircette Study Group. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. Am J Obstet Gynecol. 1998;179:S2–S8
  21. Archer DF, Maheux R, DelConte A, O'Brien FB. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol. 1999;181(5 Pt 2):39–44
  22. Boerrigter PJ, Ellman H, Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg. Clin Ther. 1999;21:118–127
  23. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55:131–137
  24. Hite RC, Bannemerschult R, Fox-Kuchenbecker P, Turck R, Brill K. Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany. Eur J Contracept Reprod Health Care. 1999;4:7–13
  25. Oakley D, Potter L, de Leon-Wong E, Visness C. Oral contraceptive use and protective behavior after missed pills. Fam Plann Perspect 1997;29:277–9, 287.
  26. Potter L, Oakley D, de Leon-Wong E, Cañamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect. 1996;28:154–158
  27. Cibula D, Karck U, Weidenhammer HG, Kunz J, Alincic S, Marr J. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg. Clin Drug Investig. 2006;26:143–150
  28. Trussell J, Hatcher RA, Cates W, Steward FH, Kost K. A guide to interpreting contraceptive efficacy studies. Obstet Gynecol. 1990;76:558–567
  29. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115–120
  30. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  31. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74:100–103
  32. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78:16–25
  33. Mishell DR. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception. 2005;71:304–305
  34. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77:249–256

☆ This study was supported by an unrestricted grant from Bayer Schering Pharma AG, Berlin, Germany.

PII: S0010-7824(09)00037-7

doi: 10.1016/j.contraception.2009.01.016

Contraception
Volume 80, Issue 1 , Pages 18-24 , July 2009

Article Tools

* Image Usage & Resolution